HC Wainwright Has Pessimistic View of CMPX FY2027 Earnings

Key Points

• HC Wainwright lowered Compass Therapeutics’ FY2027 EPS forecast to a loss of $0.57 per share from $0.56 and projects a $0.60 loss for FY2028, below the current-year consensus loss estimate of $0.47.
• Compass Therapeutics missed its latest quarterly earnings expectations, reporting a $0.13-per-share loss versus the $0.11 consensus estimate.
• The stock opened at $1.14, near its 52-week low of $1.10, despite institutional investors owning 68.43% of shares; analysts’ overall consensus remains a “Moderate Buy” with an average price target of $10.21.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at HC Wainwright cut their FY2027 EPS estimates for shares of Compass Therapeutics in a note issued to investors on Wednesday, September 23rd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.57) for the year, down from their prior forecast of ($0.56). The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Compass Therapeutics' FY2028 earnings at ($0.60) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02).

Several other brokerages have also weighed in on CMPX. Wall Street Zen lowered shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Citigroup restated a "market outperform" rating on shares of Compass Therapeutics in a research note on Wednesday. Citizens Jmp reduced their price objective on shares of Compass Therapeutics to $4.00 and set a "market outperform" rating for the company in a research note on Wednesday. Guggenheim decreased their price objective on shares of Compass Therapeutics to $4.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Lifesci Capital downgraded shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.21.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $1.14 on Friday. The firm has a market cap of $204.40 million, a price-to-earnings ratio of -2.84 and a beta of 0.95. Compass Therapeutics has a 52-week low of $1.10 and a 52-week high of $6.88. The stock has a 50-day simple moving average of $2.10 and a 200-day simple moving average of $2.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CMPX. BlackRock Inc. bought a new stake in Compass Therapeutics during the second quarter valued at about $24,707,000. BVF Inc. IL increased its stake in shares of Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after purchasing an additional 3,014,842 shares during the period. Palo Alto Investors LP bought a new position in shares of Compass Therapeutics in the second quarter worth about $12,771,670. Sofinnova Investments Inc. lifted its position in shares of Compass Therapeutics by 65.9% during the 4th quarter. Sofinnova Investments Inc. now owns 3,365,446 shares of the company's stock worth $18,072,000 after purchasing an additional 1,336,560 shares during the last quarter. Finally, NEXTBio Capital Management LP bought a new stake in Compass Therapeutics during the 4th quarter valued at approximately $5,982,000. Institutional investors own 68.43% of the company's stock.

Trending Headlines about Compass Therapeutics

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a “Market Outperform” rating while lowering its price target to $4.00, implying substantial potential upside if Compass can address the FDA’s requirements and advance tovecimig. Citizens JMP price target report
• Neutral Sentiment: A market-data update reported zero shares sold short as of September 24, producing a 0.0-day short-interest ratio. The figure may indicate limited measurable short-selling pressure, although the reported “large increase” in short interest conflicts with the zero-share total and should be treated cautiously.
• Negative Sentiment: The FDA recommended a new tovecimig trial in biliary tract cancer rather than allowing the previously contemplated filing strategy to proceed. The setback could require additional time and funding before a potential application. FDA recommends new Tovecimig trial
• Negative Sentiment: Wall Street analysts viewed the filing strategy as risky after the FDA feedback. Wedbush downgraded CMPX from “Outperform” to “Neutral” and slashed its price target from $5 to $1, while LifeSci Capital also downgraded the stock to “Hold.” These actions reinforce concerns about regulatory risk and reduced near-term catalysts. Wedbush downgrade and price target cut
• Negative Sentiment: The FDA decision erased significant market value and prompted concerns that Compass’s opportunity window is narrowing. Investors now face a longer development path, greater cash-burn risk and uncertainty over whether tovecimig can ultimately reach approval. FDA setback and market reaction

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company's research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.